Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

被引：4
作者：
Gijs F. N. Berkelmans
Jacoba P. Greving
Yolanda van der Graaf
Frank L. J. Visseren
Jannick A. N. Dorresteijn
机构：
[1] University Medical Center Utrecht,Department of Vascular Medicine
[2] University Medical Center Utrecht,Julius Center
来源：
Diagnostic and Prognostic Research | / 4卷 / 1期
关键词：
Lifetime benefit; Lifetime expectancy estimation; Cost-effectiveness; Prevention; PCSK9-mAb;
D O I：
10.1186/s41512-020-00072-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 175 条
  • [61] van der Graaf Y(undefined)undefined undefined undefined undefined-undefined
  • [62] Dennis MS(undefined)undefined undefined undefined undefined-undefined
  • [63] Burn JP(undefined)undefined undefined undefined undefined-undefined
  • [64] Sandercock PA(undefined)undefined undefined undefined undefined-undefined
  • [65] Bamford JM(undefined)undefined undefined undefined undefined-undefined
  • [66] Wade DT(undefined)undefined undefined undefined undefined-undefined
  • [67] Warlow CP(undefined)undefined undefined undefined undefined-undefined
  • [68] Criqui MH(undefined)undefined undefined undefined undefined-undefined
  • [69] Denenberg JO(undefined)undefined undefined undefined undefined-undefined
  • [70] Langer RD(undefined)undefined undefined undefined undefined-undefined
234567891011